The Second Circuit upheld the insider trading conviction of Robert Schulman, a former patent attorney at Hunton & Williams, convicted in 2017 for tipping his investment adviser, Tibor Klein, to Pfizer’s planned acquisition of King Pharmaceuticals in 2010. Schulman appealed a decision rejecting his motion to vacate his conviction on grounds of insufficient evidence. In affirming that decision, the Second Circuit concluded that the jury was not required to credit Schulman’s testimony that he intended only to brag about his knowledge of the merger to a friend.
January 10, 2019
Second Circuit upholds insider trading conviction of former lawyer
Related by Topic
Second Circuit upholds insider trading conviction of former Congressman
March 26, 2025
News Alert
Two foreign nationals charged in the United States for roles in an international insider trading scheme
March 19, 2025
News Alert
Former Biopharma executive in California settles insider trading charges
March 12, 2025
News Alert